Physician profile
Ronald Negrich
NPI 1376546655
$11,625.76
in general payments reported to CMS, 2019-2025
35 companies · $2,678 in 2025
The $2,678 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $128 · 2021: $377 · 2022: $1,811 · 2023: $3,346 · 2024: $2,232 · 2025: $2,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,187 · Education: $69.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,186.63 |
| Education | $69.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,785.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,718.18 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,210.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,138.22 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Csl Behring | $1,113.94 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $669.46 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $593.12 | 2022-2025 | Xolair |
| Stryker Corporation | $449.25 | 2019-2022 | |
| Grifols USA, LLC | $423.11 | 2019-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $397.92 | 2019-2025 | |
| Optinose US, INC. | $397.36 | 2019-2023 | |
| Pharming Healthcare, INC. | $231.50 | 2019-2025 | Ruconest |
| Pfizer INC. | $211.00 | 2022-2025 | |
| Inspire Medical Systems, INC. | $175.56 | 2022-2025 | Inspire |
| Biocryst US Sales Co., LLC | $144.50 | 2022-2025 | Orladeyo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $138.72 | 2022-2024 | Sinuva |
| Medtronic USA, INC. | $118.53 | 2019 | |
| Intersect Ent, INC. | $118.27 | 2021 | |
| Amgen INC. | $115.13 | 2022-2024 | Tezspire |
| Octapharma USA, INC. | $75.03 | 2023 | Cutaquig, Octagam Immune Globulin (Human) |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Bio Products Laboratory USA, INC. | $49.51 | 2023 | Coagadex, Gammaplex |
| Kaleo, INC. | $34.49 | 2023 | Auvi-Q |
| Shire North American Group INC | $34.09 | 2019 | |
| Lilly USA, LLC | $33.15 | 2025 | Ebglyss |
| Aerin Medical INC. | $30.57 | 2022 | |
| Abbvie INC. | $25.00 | 2023 | |
| Verona Pharma, INC. | $23.78 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $22.05 | 2021 | |
| Incyte Corporation | $17.83 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.54 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $15.19 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.15 | 2019 | |
| Alk-Abello, INC | $14.52 | 2022 | |
| Kedrion Biopharma, INC. | $14.05 | 2025 | Kedrab, Albuked, Rhogam Ultra-Filtered Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Negrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.